...
首页> 外文期刊>Cancer Medicine >Surgically resected T1‐ and T2‐stage esophageal squamous cell carcinoma: T and N staging performance of EUS and PET/CT
【24h】

Surgically resected T1‐ and T2‐stage esophageal squamous cell carcinoma: T and N staging performance of EUS and PET/CT

机译:手术切除的T1和T2期食管鳞状细胞癌:EUS和PET / CT的T和N分期表现

获取原文
   

获取外文期刊封面封底 >>

       

摘要

This study aimed to evaluate the frequency of nodal metastases and to disclose the diagnostic performance of endoscopic ultrasonography (EUS) and PET/CT in T and N staging in surgically resected early‐stage esophageal squamous cell carcinomas (eSCCs). Institutional review board approved this retrospective study with waiver of informed consent for reviewing medical record. We included 435 patients with an early T‐stage (Tis or T1a [≤T1a], T1b and T2) eSCC. The rates of metastatic lymphadenopathy were calculated. Then, the performance of EUS and PET/CT in subdividing T and N stages was assessed. 131?≤?T1a, 234 T1b, and 70 T2 eSCCs were identified. In discriminating ≤T1a from other cancers, the sensitivity, specificity, and accuracy of EUS were 60.3% (79/131), 80.3% (244/304), and 74.3% (323/435) respectively. With ROC curve analysis, cut‐off value of SUVmax 3.05 at PET provided sensitivity 74.8% (98/131), specificity 70.1% (213/304), and accuracy 71.5% (311/435) for differentiating ≤T1a eSCCs from others. Ten (7.6%) of 131?≤?T1a cancers had nodal metastasis. In discriminating N0 from node‐positive disease, sensitivity, specificity, and accuracy of EUS were 89.6% (267/298), 41.6% (57/137), and 74.5% (324/435), respectively, whereas those of PET/CT were 88.9% (265/298), 38.7% (53/137), and 73.1% (318/435) respectively. In 70% of patients with ≤T1a eSCCs, the tumor stage can be discriminated from higher stage cancers by using EUS or PET/CT. Substantial percentage (7.6%) of ≤T1a eSCC patients have nodal metastases, which are missed in more than half of the patients in clinical staging.
机译:这项研究旨在评估淋巴结转移的频率,并揭示内镜超声检查(EUS)和PET / CT在手术切除的早期食管鳞状细胞癌(eSCC)的T和N分期中的诊断作用。机构审查委员会批准了这项回顾性研究,放弃了对医疗记录的知情同意。我们纳入了435例早期T期(Tis或T1a [≤T1a],T1b和T2)eSCC患者。计算转移性淋巴结病的发生率。然后,评估了EUS和PET / CT在细分T和N阶段的性能。鉴定出131个≤T1a,234个T1b和70个T2 eSCC。在区分≤T1a与其他癌症时,EUS的敏感性,特异性和准确性分别为60.3%(79/131),80.3%(244/304)和74.3%(323/435)。通过ROC曲线分析,PET上SUVmax 3.05的临界值可将≤T1aeSCC区分为其他时,灵敏度为74.8%(98/131),特异性为70.1%(213/304)和准确性为71.5%(311/435)。 131个≤T1a癌中有10个(7.6%)有淋巴结转移。在将N0与淋巴结阳性疾病区分开时,EUS的敏感性,特异性和准确性分别为89.6%(267/298),41.6%(57/137)和74.5%(324/435),而PET / CT分别为88.9%(265/298),38.7%(53/137)和73.1%(318/435)。在> 70%≤T1aeSCC的患者中,可以使用EUS或PET / CT将肿瘤分期与晚期癌症区分开。 ≤T1aeSCC患者中有相当大的百分比(7.6%)有淋巴结转移,在临床分期中超过一半的患者漏诊了淋巴结。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号